Duolingo Inc vs Mesoblast Limited — how do they compare? Duolingo Inc trades at $151.56 (market cap $7.08B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Duolingo Inc is far larger — about 4× Mesoblast Limited's market cap, and Duolingo Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Mesoblast Limited for 14 Days on average.
| DUOL | MESO | |
|---|---|---|
Market Cap | $7.08B | $1.75B |
Volume | 729,171 | 239,027 |
Sector | Technology | Health |
52-Week High | $341.08 | $20.96 |
52-Week Low | $90.03 | $13.19 |
Typical Hold Time | 137 Days | 14 Days |
Enterprise Value | $5.85B | $1.83B |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $151.72, up 2.42% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $369M in 2022 to $1.04B in 2025 and net income surging to $414M. Recent earnings consistently beat expectations, though Q3 2026 results are pending. Analyst consensus is mixed with 37.5% buy ratings but a $140.63 price target below current levels. Operating cash flow reached $388M in 2025, supporting continued investment in user growth and AI capabilities.
Duolingo presents growth potential through AI-driven expansion and strong user metrics, but faces risks from insider selling and valuation concerns. The stock's current price exceeds analyst consensus, suggesting limited near-term upside. Key opportunities include market expansion beyond language learning, while risks involve competitive pressures and execution on monetization strategies.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →